Medical treatment;LE TRAITEMENT MEDICAL

Presse Medicale

Volumn 26, Issue 28, 1997, Pages 1357-1361

  Fenelon G ^a  

^a HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; ANTIPARKINSON AGENT;

CLINICAL EXAMINATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; PARKINSON DISEASE; REVIEW; PATHOPHYSIOLOGY;

ANTIPARKINSON AGENTS; HUMANS; LEVODOPA; PARKINSON DISEASE;

EID: 0342891346     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Guillard A. La maladie de Parkinson, 20 ans après. Presse Med 1987 ; 16:1565-6.
2. Fénelon G. Diagnostic et évolution (sous traitement) de la maladie de Parkinson. Rev Prat 1997 ; 47:1062-7.
3. Pollak P. Mécanismes et traitements de la maladie de Parkinson. Rev Prat 1997 ; 47:1068-75.
4. Clarke CE. Does levodopa therapy delay death in Parkinson's disease? A review of the evidence. Mov Disord 1995 ; 10:250-6.
5. Montastruc JL, Rascol O, Senard JM, Rascol A. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry 1994 ; 57:1034-8.
6. Allain H, Bentué-Ferrer D. Maladie de Parkinson : interrogations et solutions. Presse Med 1997 ; 26:909-15.
7. Montastruc JL, Rascol O, Senard JM. Current status of dopamine agonists in Parkinson's disease management Drugs 1993 ; 46:384-93.
8. Lees AJ. On behalf of the Parkinson's disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 1995 ; 311:1602-7.
9. Olanow CW, Fahn S, Langston JW, Godbold J. Selegiline and mortality in Parkinson's disease. Ann Neurol 1996 ; 40:841-5.
10. Fahn S. Is levodopa toxic? Neurology 1996 ; 47(suppl 3)S184-95.
11. Factor SA, Weiner WJ. Early combination therapy with bromocriptine and levodopa in Parkinson's disease. Mov Disord 1993 ; 8:257-62.
12. Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology 1987 ; 37:826-8.
13. Block G, Liss C, Reines S, Irr J, Nibbelink DC, the CR FIRST Study Group. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's dsase. A multicenter 5-year study. Eur Neurol 1997 ; 37:23-7.
14. Dupont E, Andersen A, Boas J et al. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurol Scand 1996 ; 93:14-20.
15. Rondot P, Ziégler M. Activity and acceptability of piribedil in Parkinson's disease: a multicentre study. J Neurol 1992;239(suppl1):S28-34.